CO32 Heterotopic Ossification in Palovarotene-Treated and Untreated Individuals with Fibrodysplasia Ossificans Progressiva: Matched and Weighted Analyses

Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare, genetic disorder characterized by progressive heterotopic ossification (HO), leading to cumulative disability. Post hoc analyses of HO volume changes observed during the phase III MOVE trial (NCT03312634) versus a non-interventional natural history study (NHS; NCT02322255) allow further evaluation of palovarotene for the treatment of FOP.